Tradestie Institutional Equity Comparison Engine · Market Close Nov 19, 2026

BEAM vs LCTX: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

LCTX Wins Head-to-Head Institutional Verdict (3–2 across 6 Pillars · 7–2 Matrix Metrics)

LCTX Overall Winner 6-Pillar Tally: BEAM 2 – 3 LCTX (1 Tie) Matrix Metrics: BEAM 2 – 7 LCTX

As of Nov 19, 2026, Lineage Cell Therapeutics, Inc. (LCTX) is the stronger overall head-to-head candidate over Beam Therapeutics Inc. (BEAM) in the Tradestie Institutional Equity Comparison Engine, winning 7–2 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). BEAM carries a Unified Composite Score of 57.3/100 (HOLD) at $20.94 (N/M Forward P/E, -267.7% operating margin), whereas LCTX carries 58.9/100 (HOLD) at $0.82 (30.7x Forward P/E, -280.3% operating margin).

  • Technical & Structure Timing Caution: BEAM is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 37.0); meanwhile LCTX is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 38.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About BEAM vs LCTX
BEAM NASDAQ
Beam Therapeutics Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$20.94
-0.33% 1D
Market Cap $2.2B
TTM Revenue $147M
Forward P/E N/M
Beta / 30D Vol 2.24β · 86% Vol
Unified Composite Score
57.3 / 100 HOLD
Tech 63.0 Fund 60.0 Flow 68.0 Mom 60.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -5.2%), weak momentum, RSI 37
RSI-14: 37.0 · SMA20: $24.92 · SMA50: $24.70
LCTX NYSE American Head-to-Head Winner
Lineage Cell Therapeutics, Inc.
Biological Products, (No Disgnostic Substances)
$0.82
-2.21% 1D
Market Cap $212.1M
TTM Revenue $11M
Forward P/E 30.7x
Beta / 30D Vol 1.36β · 79% Vol
Unified Composite Score
58.9 / 100 HOLD
Tech 65.0 Fund 54.0 Flow 65.0 Mom 45.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -4.2%), weak momentum, RSI 38
RSI-14: 38.3 · SMA20: $0.98 · SMA50: $0.98

6-Pillar Scorecard Institutional Category Breakdown (BEAM 2 – 3 LCTX)

Columns: Metric · BEAM · LCTX
1. Valuation Multiples LCTX
Forward P/E N/M 30.7x
Trailing P/E N/M 30.7x
PEG Ratio N/M 10.64x
EV / Revenue 15.2x 16.3x
2. Growth & Scale BEAM
Revenue Growth (YoY) -96.8% -61.0%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $147M $11M
Market Cap $2.2B $212.1M
3. Profitability & Quality LCTX
Gross Margin N/A -95.0%
Operating Margin -267.7% -280.3%
Net Profit Margin -73.9% 16.2%
Return on Equity (ROE) -11.3% 4.3%
4. Balance Sheet & Cash Flow LCTX
Cash Generation (TTM) -$398M -$24M
Cash Flow Margin N/A N/A
Net Cash / Leverage $31M Net Debt (0.26x D/E) $35M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning BEAM
Options Structure Phase BREAKDOWN BREAKDOWN
Current IV / %ile 107.8% (69th %ile) 896.2% (100th %ile)
Put/Call OI Skew 1.11x (Balanced) 1.10x (Balanced)
OBV Trend / Tech Phase DISTRIBUTION · Markdown DISTRIBUTION · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: BEAM (2) vs LCTX (7)
Institutional Metric BEAM LCTX Criterion Row Edge
Market Capitalization
Scale
$2.2B $212.1M Larger Scale BEAM
Trailing P/E Ratio
Valuation
N/M 30.7x Lower Multiple LCTX
Forward P/E Ratio
Valuation
N/M 30.7x Lower Multiple LCTX
Revenue Growth (YoY)
Growth
-96.8% -61.0% Higher Growth LCTX
Operating Margin (TTM)
Profitability
-267.7% -280.3% Higher Margin BEAM
Net Profit Margin
Profitability
-73.9% 16.2% Higher Margin LCTX
Return on Equity (ROE)
Capital Efficiency
-11.3% 4.3% Higher ROE LCTX
52-Week Range Position
Momentum
4% ($20–$38) 4% ($1–$2) Stronger Trend Tie
Beta / 30D Volatility
Risk Regime
2.24β · 86% Vol 1.36β · 79% Vol Lower Realized Risk LCTX
Unified Institutional Score
Composite Signal
57.3 / 100 (HOLD) 58.9 / 100 (HOLD) Higher Composite LCTX
Trailing 12M Revenue (USD)
Operating Scale
$147M $11M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A -95.0% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 15.2x EV/Rev 10.64x PEG · 16.3x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$398M ($31M Net Debt (0.26x D/E)) -$24M ($35M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon LCTX +1.88 pp
BEAM: -15.7% · LCTX: -13.82%
3M Horizon LCTX +5.57 pp
BEAM: -29.64% · LCTX: -24.07%
6M Horizon BEAM +13.56 pp
BEAM: -24.32% · LCTX: -37.88%
1Y Horizon BEAM +49.2 pp
BEAM: -4.47% · LCTX: -53.67%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period BEAM Revenue LCTX Revenue BEAM Op. Margin LCTX Op. Margin Margin Leader
FY2018 N/A $0M N/A -837.9% LCTX
FY2019 $0M $0M -417522.2% -1106.0% LCTX
FY2020 $0M $0M -553166.7% -1448.4% LCTX
FY2021 $50M $0M -757.0% -1133.6% BEAM
FY2022 $60M $10M -555.6% -153.2% LCTX
FY2023 $380M $10M -46.7% -276.5% BEAM
FY2024 $60M $10M -654.3% -226.1% LCTX
FY2025 $140M $10M -274.6% -251.6% LCTX

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
BEAM BREAKDOWN
106d in phase · OBV DISTRIBUTION
Current IV 107.8%
IV Percentile 69th %ile
Put/Call OI Skew 1.11x (Balanced)
IV Regime Elevated (60th–80th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow DISTRIBUTION
Exact BEAM Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
LCTX BREAKDOWN
6d in phase · OBV DISTRIBUTION
Current IV 896.2%
IV Percentile 100th %ile
Put/Call OI Skew 1.10x (Balanced)
IV Regime Extreme (>80th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow DISTRIBUTION
Exact LCTX Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
BEAM Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $2.2B market capitalization and -267.7% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
LCTX Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $212.1M market capitalization and -280.3% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ BEAM vs LCTX Key Questions & Quantitative Answers

As of Nov 19, 2026, Lineage Cell Therapeutics, Inc. (LCTX) is the stronger overall head-to-head candidate over Beam Therapeutics Inc. (BEAM) in the Tradestie Institutional Equity Comparison Engine, winning 7–2 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). BEAM carries a Unified Composite Score of 57.3/100 (HOLD) at $20.94 (N/M Forward P/E, -267.7% operating margin), whereas LCTX carries 58.9/100 (HOLD) at $0.82 (30.7x Forward P/E, -280.3% operating margin). Technical & Structure Timing Caution: BEAM is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 37.0); meanwhile LCTX is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 38.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

BEAM leads the Growth & Scale pillar: BEAM posts -96.8% YoY revenue growth and +0.0% YoY earnings growth on $147M TTM revenue (N/A gross margin, -267.7% operating margin), compared with LCTX at -61.0% YoY revenue growth and +0.0% YoY earnings growth on $11M TTM revenue (-95.0% gross margin, -280.3% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), BEAM cumulative revenue shifted +180.0% while LCTX shifted +0.0%. In operating R&D and SG&A reinvestment, BEAM deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for LCTX.

LCTX screens cheaper on headline valuation multiples. BEAM trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 15.2x EV/Revenue (unreported FCF margin), whereas LCTX trades at 30.7x Forward P/E, 30.7x Trailing P/E, 10.64x PEG, and 16.3x EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against BEAM (-11.3% ROE) versus LCTX (4.3% ROE) capital efficiency.

In options market volatility and institutional positioning, BEAM carries 107.8% implied volatility (69th %ile, Elevated (60th–80th %ile)), a 1.11x (Balanced) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (2.24β · 86% Vol realized risk). By comparison, LCTX carries 896.2% implied volatility (100th %ile, Extreme (>80th %ile)), a 1.10x (Balanced) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (1.36β · 79% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 19, 2026. For educational research only; not investment advice.